

Research

Open Access

Follicle-stimulating hormone (FSH) activates extracellular signal-regulated kinase phosphorylation independently of beta-arrestin- and dynamin-mediated FSH receptor internalization

Vincent Piketty, Elodie Kara, Florian Guillou, Eric Reiter and Pascale Crepieux*

Address: Laboratoire de Physiologie de la Reproduction et des Comportements, Institut National de la Recherche Agronomique/Centre National pour la Recherche Scientifique/Université de Tours/Haras Nationaux/Institut Fédératif de Recherche 135, Centre de Recherches de Tours, 37380 Nouzilly, France

Email: Vincent Piketty - piketty@tours.inra.fr; Elodie Kara - kara@tours.inra.fr; Florian Guillou - guillou@tours.inra.fr; Eric Reiter - reiter@tours.inra.fr; Pascale Crepieux* - crepieux@tours.inra.fr

* Corresponding author

Published: 20 June 2006

Received: 11 April 2006

Reproductive Biology and Endocrinology 2006, 4:33 doi:10.1186/1477-7827-4-33

Accepted: 20 June 2006

This article is available from: <http://www.rbej.com/content/4/1/33>

© 2006 Piketty et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The follicle-stimulating hormone receptor (FSH-R) is a seven transmembrane spanning receptor (7TMR) which plays a crucial role in male and female reproduction. Upon FSH stimulation, the FSH-R activates the extracellular signal-regulated kinases (ERK). However, the mechanisms whereby the agonist-stimulated FSH-R activates ERK are poorly understood. In order to activate ERK, some 7 TMRs require beta-arrestin-and dynamin-dependent internalization to occur, whereas some others do not. In the present study, we examined the ability of the FSH-activated FSH-R to induce ERK phosphorylation, in conditions where its beta-arrestin- and dynamin-mediated internalization was impaired.

Methods: Human embryonic kidney (HEK) 293 cells were transiently transfected with the rat FSH-R. Internalization of the FSH-R was manipulated by co-expression of either a beta-arrestin (319–418) dominant negative peptide, either an inactive dynamin K44A mutant or of wild-type beta-arrestin 1 or 2. The outcomes on the FSH-R internalization were assayed by measuring 125I-FSH binding at the cell surface when compared to internalized 125I-FSH binding. The resulting ERK phosphorylation level was visualized by Western blot analysis.

Results: In HEK 293 cells, FSH stimulated ERK phosphorylation in a dose-dependent manner. Co-transfection of the beta- arrestin (319–418) construct, or of the dynamin K44A mutant reduced FSH-R internalization in response to FSH, without affecting ERK phosphorylation. Likewise, overexpression of wild-type beta-arrestin 1 or 2 significantly increased the FSH-R internalization level in response to FSH, without altering FSH-induced ERK phosphorylation.

Conclusion: From these results, we conclude that the FSH-R does not require beta-arrestin- nor dynamin-mediated internalization to initiate ERK phosphorylation in response to FSH.

Background

ERK mitogen-activated protein (MAP) kinases are commonly activated by 7TMRs, which leads to a wide array of cellular processes including cell proliferation and cell differentiation. In the last decade, a tremendous amount of works have been dedicated to elucidate the cell signaling mechanisms whereby 7TMRs activate ERK. To achieve ERK activation, some 7TMRs, such as the lutropin receptor [1], rely solely on G protein activation and to second messenger production. Besides, several reports support the view that MAP kinase activation requires receptor internalization, mediated by β -arrestins [2]. Originally, β -arrestins have been viewed as responsible for receptor desensitization, by uncoupling an agonist-activated receptor from its effector G proteins, and then by driving the uncoupled receptor to clathrin-coated pits [3,4]. β -arrestin-dependent internalization of 7TMRs involves the direct interaction of the carboxy-terminal part of β -arrestins with the β 2-adaptin subunit of the adaptor protein (AP)-2 complex [5]. Mutation of two arginines in this region abrogates both the β -arrestin/AP2 interaction and the clustering of β 2-adrenergic receptor into clathrin-coated pits [6]. Furthermore, β -arrestins bind directly to clathrin *in vitro* [7]. As endocytic adaptors, β -arrestins also interact with the small GTPase ADP-ribosylation factor (ARF)-6 and its exchange factor nucleotide-binding site opener (ARNO), and with the N-ethylmaleimide-sensitive fusion protein (NSF) [8]. In HEK 293 cells stimulated by isoproterenol, overexpression of β -arrestin V53D, or of a β -arrestin (319–418) peptide, both impaired in their receptor-binding ability [9], not only reduces the β 2-adrenergic receptor internalization level, but also decreases ERK activation [10]. Likewise, inhibition of β -arrestin 1 or 2 expression by RNA interference levels off the isoproterenol-induced ERK phosphorylation [11]. Besides, fission of the clathrin endocytic vesicle from the plasma membrane is in part achieved by the GTPase dynamin. Overexpression of a defective K44A dynamin mutated in its catalytic domain [12] impairs both receptor internalization as well as ERK stimulation transduced by the δ -opioid receptor [13]. In sharp contrast, some 7TMRs, such as the α 2a adrenergic receptor [14], activate ERK without being internalized, whereas some others, such as the metabotropic glutamate mGlu1 receptor, require β -arrestins to activate ERK, but not through their endocytosis-promoting ability [15]. Therefore, whether 7TMR-mediated ERK activation will depend on β -arrestin-promoted internalization or not seems to be a receptor-related issue.

The follicle-stimulating hormone receptor (FSH-R) is a 7TMR whose main effector is adenylate cyclase [16]. Once bound to its agonist, the FSH-R gets phosphorylated by G protein-coupled receptor kinases (GRKs), recruits β -arrestins [17] and undergoes internalization [18-21].

Overexpression of β -arrestin 1 or 2 or of the β -arrestin (319–418) peptide respectively reduces or increases cAMP in response to FSH, as measured by a luciferase gene reporter assay [17,22]. The FSH-R is expressed by two cell types of the gonad, namely Sertoli cells in the testis, and granulosa cells in the ovarian follicle [23]. ERK MAP kinases have been shown to be activated upon FSH stimulation of primary cultures of both cell types [24-26], and this signaling pathway mediates the mitogenic response of Sertoli cells to the hormone [24]. Previously, overexpression of β -arrestin 1 or 2 [21] or of the β -arrestin (319–418) peptide and of the dynamin K44A [20] mutant had been shown to affect the FSH-R internalization. But to date, nothing is known about the role of β -arrestin-dependent internalization in ERK activation by the FSH-R. Here, we addressed this question in HEK 293 cells transiently expressing the FSH-R, by enhancing internalization with overexpressed wild-type β -arrestins or by interfering with receptor internalization with the β -arrestin (319–418) construct or by the dynamin K44A mutant.

Methods

Materials

Porcine FSH (apparent molecular weight = 33,500 g/mol) was purified by Dr Jean Closset (Université de Liège, Belgium) [27]. Amphotericin B, penicillin, streptomycin, glutamin, phenylmethylsulfonyl (PMSF), Na_3VO_4 , leupeptin, pepstatin and aprotinin were from Sigma Chemical Co (St. Louis, MO). Dulbecco's minimum essential medium (DMEM), minimum essential medium (MEM) with Earle's salt, foetal calf serum (FCS), non essential amino acids, trypsin-EDTA were all from Gibco-BRL Life Technologies (Gaithersburg, MD). The Transfast™ transfection reagent was from Promega Corp., Madison, WI.

Plasmids

The pRK-FSHR/3 was a kind gift of Dr R. Sprengel (Heidelberg, Germany). The pCMV5-rat β -arrestin 1 and pCMV5-rat β -arrestin 2 were gifts of Dr R.J. Lefkowitz (Durham, NC). The pcDNA3- β -arrestin (319–418) was given by Dr J.L. Benovic (Philadelphia, PA) and the pcDNA3-dynamin-K44A plasmid was provided by Dr S.L. Schmid (La Jolla, CA).

Cell culture and transfection

HEK 293 cells were grown in MEM supplemented with 20 μM glutamin, 100 μM non essential amino acids, 10% heat-inactivated FCS, 10 U/ml penicillin and 10 $\mu\text{g}/\text{ml}$ streptomycin.

HEK 293 cells were grown and transfected in 75 cm^2 flasks. Cells were maintained at 37°C in a humidified atmosphere of 5% CO_2 . Fifty to eighty % confluent cells in FCS-free medium were incubated for 1 hour with Transfast reagent (800 ng per cm^2 culture) and plasmid DNA

encoding the FSH-R (200 ng per cm²) and β -arrestin (319–418) (600 ng per cm²) or wild-type β -arrestins (200 ng per cm²) or dynamin K44A (600 ng per cm²), unless otherwise stated. Empty plasmid was added in every culture wells to equalize transfected plasmid concentrations. Twenty-four hours after transfection, cells were treated for 90 sec with 3 ml 0.25% trypsin and 1 mM EDTA, centrifuged 10 min at 100 g and seeded in 9.6 cm² culture plates with a dilution factor of 0.4. Seventy hours after transfection, cells were FCS-starved for 2 hours in 1 ml, and then stimulated with 1 to 10 nM pFSH. Media were collected and cells were scrapped. For further Western blot analysis, HEK 293 cells were scrapped directly in Laemmli sample buffer (Tris HCl 0.25 M pH 6.8, 5% SDS, 50% glycerol, 50 mM β -mercaptoethanol, 0.01% bromophenol blue).

Western blots

HEK 293 cell lysates were preincubated for 30 min at 37°C before gel loading. Samples were resolved by SDS-PAGE, electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (NEN Life Science Products, Boston, MA) and hybridized with the antibodies mentioned in the following. Anti-p44^{ERK1}/p42^{ERK2} rabbit polyclonal antibody (Cell Signaling Technology Inc.) was used at 1:1,000 dilution. The anti-ERK rabbit polyclonal antibody purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), was used at 1:10,000 dilution. The anti-arrestin A1CT polyclonal antibody kindly provided by R.J. Lefkowitz (Durham, NC), was used at a 1:10,000 dilution. It recognizes the C-terminus of β -arrestins, and therefore recognizes endogenous, overexpressed wild-type as well as overexpressed (319–418) β -arrestins. Primary antibodies were incubated with membranes in TBS (20 mM Tris, 150 mM NaCl) 0.1% Tween-20 supplemented with 5% unfat milk for 18 hours at 4°C under constant agitation. Horseradish peroxidase-coupled anti-rabbit antibody (Bio-Rad Laboratories Inc., Marnes-la-Coquette, France) was used at 1:5,000 dilution, to detect antigen-antibody interactions by enhanced chemiluminescence (NEN Life Science Products). To monitor protein loading, a first Western blot was hybridized with the anti-P-ERK antibody, the membrane was stripped 30 min at 50°C in 100 mM β -mercaptoethanol, 2% SDS, and rinsed twice for 10 min at room temperature in 150 mM NaCl, 0.05% Triton X100. Then, the membrane was reprobed with anti-ERK antibody. When β -arrestins were also probed with the A1CT antibody, a second SDS-PAGE was achieved with equal quantities of proteins as in the first gel, and Western blot was carried on. The ratio of phosphorylated ERK2 to total ERK2 was quantified using the ImageMaster 1D Elite version 4 Software (Amersham Biosciences, Arlington Heights, IL) and the results were expressed as phospho-ERK/ERK.

¹²⁵Iodo-FSH labelling (iodination)

Five μ l (70 pmol) pFSH were incubated for 20 minutes with 25 μ g of lyophilized iodo-gen and 2 μ l containing 100 μ Ci ¹²⁵Iodine with specific activity of 2,670 Ci/mmol. Separation of ¹²⁵Iodo-FSH was performed on a Sephadex G50 column and the iodination efficiency was around 65%.

Cell surface and internalized ¹²⁵Iodo-FSH binding

Internalization assay procedures were described previously [18]. Briefly, cells plated in 9.6 cm² wells were placed in 950 μ l of Waymouth's MB752/1 containing 1 mg/ml bovine serum albumin (BSA) and 20 mM Hepes pH 7.4 for 2 h at 37°C. Each well received around 500,000 cpm ¹²⁵I-FSH (160 pM final concentration) alone or added with unlabelled pFSH (160 nM final concentration) in 50 μ l. Total and non-specific binding were assayed in triplicates. At the indicated timepoints, cells were placed on ice and washed three times with 1 ml of cold Hanks' balanced salt solution containing 1 mg/ml BSA. The surface-bound hormone was then released by incubating cells in 1 ml of cold 50 mM glycine, 150 mM NaCl, pH 3.0 for 4 min. The buffer was withdrawn and counted, the cells were collected with 300 μ l of 0.5 N NaOH and were also counted.

Expression of results and statistical analysis

Results were expressed as mean + S.E.M., unless otherwise indicated. Comparison of the results was based on variance analysis. A probability (P) value below 5% was considered as significant.

Results

FSH stimulates ERK phosphorylation in HEK 293 cells

In HEK 293 cells transiently expressing the rat FSH-R, FSH stimulated ERK phosphorylation in a dose-dependent manner (Figure 1A, 1B). Based on these data, the optimal dose of FSH to be used in the following was determined as 3 nM FSH, which is close to the K_D of FSH in testicular fractions [23]. In a time-course experiment, FSH stimulated ERK phosphorylation as soon as 2 minutes of exposure. ERK phosphorylation peaked around 6 min, then declined slowly, since 44% of the maximum phosphorylation was still observed by 15 min of FSH stimulation (Figure 1C, 1D). By 60 min, there was still more than twice as much the basal level of ERK phosphorylation (data not shown). No ERK phosphorylation was detected in cells exposed to a vehicle or in control cells transfected with an empty plasmid (Figure 1D).

Characterization of the FSH-R internalization

In order to evaluate whether blocking internalization impacts on FSH-stimulated ERK phosphorylation, it was first necessary to characterize the parameters of FSH-R internalization in our experimental conditions. For that




Figure 1

FSH stimulates ERK phosphorylation in HEK 293 cells expressing the rat R-FSH. **A:** Quantification of the P-ERK/ERK ratio (n = 3 independent experiments) in response to increasing doses of FSH for 6 min. **B:** Representative autoradiograph of dose-dependent FSH-induced ERK phosphorylation. **C:** Quantification of P-ERK (n ≥ 3 experiments) in response to FSH stimulation from 2 to 15 min. **D:** Representative autoradiograph showing the time-course of FSH-induced ERK phosphorylation in cells expressing the FSH-R or transfected with an empty plasmid, as indicated. In **1A** and **1C**, results are expressed as means + S.E.M. of fold stimulation over basal level. Shared superscripts indicate no significant difference, while different superscripts indicate significant differences at the P > 0.05 level.




Figure 2

Kinetics of FSH-R internalization. Binding experiments showing internalized and cell-surface FSH-R (A) or showing the internalization ratio (B) in the same culture wells, for times ranging from 4 to 60 min of stimulation with ¹²⁵I-pFSH. Results are expressed as the ratio of internalized ¹²⁵I-FSH binding versus total (membrane + internalized) binding. Data show the mean + S.E.M. of 5 independent experiments.

purpose, cells were placed in the same experimental conditions as those used to visualize ERK phosphorylation, except that pFSH was replaced by I¹²⁵-labeled pFSH. The kinetics of FSH binding we obtained (Figure 2A) were in agreement with reference data obtained in testicular fractions [28] and in HEK 293 cells exogenously expressing the FSH-R [28]. The ratio of internalized ¹²⁵I-FSH binding versus total binding increased rapidly up to 10 min, then more slowly over time (Figure 2B), so that internalization

of the FSH-R in response to FSH did not exceed 50% over time.

The dominant negative β -arrestin (319–418) construct or the dynamin K44A mutant reduces the ratio of internalized ¹²⁵Iodo-FSH binding without altering FSH-induced ERK phosphorylation

We next investigated whether FSH-R internalization was required to generate the FSH-induced ERK response.

Transfection of 600 ng of β -arrestin (319–418) or of the GTPase-deficient dynamin K44A mutant reduced the ratio of internalized FSH-R after 8 min of ^{125}I -FSH exposure, a timepoint when ERK phosphorylation peaked (Figure 3A). Even in the presence of 2 μg of β -arrestin (319–418) or dynamin K44A, it was not possible to decrease further the internalization level, suggesting that at maximum 40% inhibition of internalization could be reached in these conditions. In time-course experiments with ^{125}I -FSH exposure from 4 to 60 min, the level of inhibition of FSH-R internalization by β -arrestin (319–418) (Figure 3B) or by dynamin K44A (Figure 3C) was constant over time. Transfection of β -arrestin (319–418), visualized by immunoreaction with the A1CT anti-arrestin antibody, did not alter ERK phosphorylation levels after 4, 8 or 12 minutes of FSH exposure (Figure 4A). Likewise, transfection of the K44A dynamin mutant left the FSH-stimulated ERK phosphorylation level unchanged. Figure 4B shows that there is no difference in the quantification of phosphorylated *versus* total ERK between cells transfected with β -arrestin (319–418) or dynamin K44A and control cells. Therefore, inhibiting β -arrestin- or dynamin-mediated FSH-R internalization did not alter FSH-induced ERK phosphorylation.

Overexpression of wild-type β -arrestin 1 or 2 increases internalized ^{125}I -FSH binding without affecting FSH-induced ERK phosphorylation

Symmetrically, overexpression of wild-type β -arrestin 1 or β -arrestin 2 enhanced the FSH-R internalization (Figure 5A). In time-course experiments with ^{125}I -FSH exposure from 4 to 60 min, the increase in FSH-R internalization by β -arrestin 1 or 2 was constant over time (Figure 5B). β -arrestin 2 appeared slightly more effective than β -arrestin 1 in enabling internalization of the FSH-R. However, expression of both arrestins had no additive effect. β -arrestin overexpression led to more than 70% of the control level of FSH-R internalization. The actual level of overexpressed β -arrestins was individually immunodetected with the A1CT antibody (Figure 5C). The increase in FSH-R internalization obtained after transfection of 50 or 200 ng of β -arrestin 1 or of β -arrestin 2 did not alter FSH-induced ERK phosphorylation. Both quantities of β -arrestins led to a plateau in the FSH-R internalization level (Figure 5C, lower part). Figure 5D shows that there is no difference in the quantification of phosphorylated *versus* total ERK between cells overexpressing β -arrestin 1 or β -arrestin 2 and control cells.

In conclusion, these data show that an increase in β -arrestin-mediated FSH-R internalization level had no effect on the ERK response.

Discussion

Our results clearly show that interfering with the FSH-R internalization by β -arrestin (319–418) or by dynamin K44A did not affect the ability of FSH to enhance ERK phosphorylation. Consistently, overexpression of β -arrestins 1 and 2 increased the percentage of FSH-R internalization but did not alter the ability of FSH to increase ERK phosphorylation. Therefore, we conclude that β -arrestin-dependent internalization is not required for FSH-induced ERK phosphorylation.

Our data are concordant with previous reports showing that expression of β -arrestin (319–418) or of dynamin K44A impaired the FSH-R internalization rate [18,20,29]. Here, we extended these works, but even by increasing doses of interfering mutants, and in kinetics experiments, the FSH-R internalization could not be inhibited by more than 50%, in agreement with these reports. To validate our experimental framework, we also confirmed that overexpression of β -arrestin 1 [21] and β -arrestin 2 [20,21] enhanced the FSH-R internalization rate. By a similar approach, it is possible to enhance ERK phosphorylation in response to angiotensin II [30].

Interestingly, our results suggest a difference in the efficiency of β -arrestins 1 and 2 to promote FSH-R internalization, in contrast to previously reported data [21]. Non-redundant functions for β -arrestins have previously been documented for other receptors. For example, whereas internalization of the agonist-induced β_2 -adrenergic receptor is insensitive to β -arrestin-1 depletion by RNA interference, β -arrestin-2 depletion has a dramatically inhibitory effect [31]. In addition, a reduction in β -arrestin 2, but not in β -arrestin 1 expression by siRNA, inhibits the ability of Angiotensin II to increase ERK phosphorylation, in HEK 293 cells transfected with the Angiotensin II type 1A receptor [32]. Likewise, vasopressin type 2 receptor-mediated ERK phosphorylation is sensitive to β -arrestin 2, but not to β -arrestin 1 suppression [33]. In sharp contrast, β -arrestin 1 and 2 have similar effects on parathyroid hormone receptor-mediated [34] or on β_2 -adrenergic receptor-dependent ERK activation [11]. Therefore, whether or not each β -arrestin has a specific action seems to vary according to the receptor.

Albeit the FSH-R internalization level does not seem crucial for FSH-induced ERK phosphorylation, we cannot exclude an internalization-independent role of β -arrestins to achieve this response. Importantly, in the last years, β -arrestin function has extended far beyond receptor desensitization and endocytosis, by virtue of their ability to scaffold MAP kinase signaling modules, as well as elements of the inositolide-dependent pathways [35,36]. It has been extensively reported that β -arrestins can scaffold an entire MAP kinase cascade, including a MAPKKK such as Raf-1 or




Figure 3

Inhibitory effect of the dynamin K44A and β -arrestin (319–418) constructs on the FSH-R internalization in HEK 293 cells after 8 minutes ^{125}I -FSH stimulation. Cells were transfected in triplicates with a plasmid encoding the FSH-R and with 600 ng or 2 μg of empty plasmid or plasmid expressing dynamin K44A or β -arrestin (319–418). B: Kinetics of FSH-R internalization in the presence (triangles) or absence (diamonds) of overexpressed (319–418) construct. C: Kinetics of FSH-R internalization in the presence (triangles) or absence (diamonds) of overexpressed K44A dynamin.




Figure 4

Inhibition of dynamin- or β-arrestin-mediated FSH-R internalization does not impair FSH-induced ERK phosphorylation. A: Immunodetection of P-ERK, of endogenous β-arrestins and of β-arrestin (319–418) as indicated, following 4, 8 and 12 min of FSH stimulation. n.s. = non specific. MWM = molecular weight marker (kDa). B: Quantification of P-ERK in response to 8 min of FSH stimulation (n = 3 independent experiments).

ASK1, a MAPKK such as MKK4/7 or MEK1/2 and a MAPK such as ERK [37], JNK [38] and p38 [39].

The mechanism of ERK activation is a crucial determinant of ERK-induced physiological response. A two-step process has recently been proposed to lead to ERK activation in response to 7TMR agonists: an early G protein-dependent mechanism followed by a β-arrestin-mediated mechanism leading to ERK phosphorylation by 10 minutes of

Angiotensin II exposure [40]. Whereas the early and transient G-protein-activated ERK translocates to the nucleus to phosphorylate its target transcriptional regulators, the late and sustained β-arrestin-activated ERK accumulates in a pool of cytoplasmic vesicles [41] to constrain ERK activity to phosphorylation of its extra-nuclear targets. Likewise, retention of the proteinase-activated receptor-2 in the cytoplasm by a β-arrestin-containing signaling complex retains ERK in the cytoplasm, thus preventing a




Figure 5

Increasing β-arrestin-mediated internalization of the FSH-R does not change ERK phosphorylation. A. FSH-R internalization after 8 minutes of ¹²⁵I-FSH exposure. Cells were transfected in sextuplicates with the FSH-R and with 2 μg β-arrestin 1 or β-arrestin 2 or of empty plasmid. B: Kinetics of FSH-R internalization in the absence (diamonds) or presence of overexpressed β-arrestin 1 (squares) or β-arrestin 2 (triangles). C: immunodetection of P-ERK and of endogenous β-arrestin 1 or 2 as indicated, following 6 min of FSH exposure. The percentage +/- S.E.M. of FSH-R internalization in the presence of 50 or 200 ng of β-arrestins is indicated below the autoradiograms. D: Quantification of P-ERK (n = 4 independent experiments) in response to 6 min of FSH stimulation.

mitogenic response [37]. Therefore, fine-tuning the mechanism of ERK activation by G protein and/or by β -arrestins is a major determinant of an agonist-induced ultimate cellular response. Our own studies on the FSH-R using β -arrestin siRNA indicate that prolonged ERK phosphorylation upon FSH stimulation requires β -arrestins (See additional file 1: Kara *et al.*, submitted). Therefore, since β -arrestins are required for FSH-induced ERK phosphorylation, and since ERK phosphorylation occurs even though internalization is markedly reduced, our results raise the appealing possibility that FSH would activate ERK at the plasma membrane. β -arrestins would assemble their MAPK signaling modules at the plasma membrane, or, alternatively, they would recruit a preformed complex, similarly to the JNK3 signaling module [38]. This point requires further investigations.

In granulosa cells, B-Raf, Rap-1 and MEK are constitutively active and lead to ERK phosphorylation. However, ERK is constitutively dephosphorylated by a phosphatase which is blocked by FSH, in a G-protein/PKA-dependent manner [26]. This leads to ERK translocation to the nucleus, as further substantiated by our own data obtained in Sertoli cells [24]. These results do not exclude that β -arrestins could intervene later in the kinetics of activation, to sequester activated ERK in the cytosol, as previously reported for other GPCRs, such as the AT1a-R [30] or the PAR-2 [37].

In conclusion, our study provide clear evidence that, in contrast to many 7TMRs, β -arrestin-mediated FSH-R internalization is not required for ERK activation by FSH.

Acknowledgements

The authors would like to thank Dr R.J. Lefkowitz, Dr R. Sprengel, Dr J.L. Benovic, and Dr S. Schmid for kindly providing plasmids and antibodies.

E.K. was funded by fellowships from the Région Centre, the Fondation pour la Recherche Médicale, and the Fonds d'Aide à la Recherche Organon. This work was funded by the Institut National de la Recherche Agronomique and by the Centre National de la Recherche Scientifique.

References

- Hirakawa T, Ascoli M: **The lutropin/choriogonadotropin receptor-induced phosphorylation of the extracellular signal-regulated kinases in leydig cells is mediated by a protein kinase a-dependent activation of ras.** *Mol Endocrinol* 2003, **17(11)**:2189-2200.
- Shenoy SK, Lefkowitz RJ: **Seven-transmembrane receptor signaling through beta-arrestin.** *Sci STKE* 2005, **2005(308)**:cm10.
- Ferguson SS: **Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling.** *Pharmacol Rev* 2001, **53(1)**:1-24.
- Barak LS, Ferguson SS, Zhang J, Caron MG: **A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation.** *J Biol Chem* 1997, **272(44)**:27497-27500.
- Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, Barak LS: **The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis.** *Proc Natl Acad Sci USA* 1999, **96(7)**:3712-3717.
- Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG: **The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits.** *J Biol Chem* 2000, **275(30)**:23120-23126.
- Goodman OB Jr, Krupnick JG, Gurevich VV, Benovic JL, Keen JH: **Arrestin/clathrin interaction. Localization of the arrestin binding locus to the clathrin terminal domain.** *J Biol Chem* 1997, **272(23)**:15017-15022.
- Lefkowitz RJ, Shenoy SK: **Transduction of receptor signals by beta-arrestins.** *Science* 2005, **308(5721)**:512-517.
- Krupnick JG, Santini F, Gagnon AW, Keen JH, Benovic JL: **Modulation of the arrestin-clathrin interaction in cells. Characterization of beta-arrestin dominant-negative mutants.** *J Biol Chem* 1997, **272(51)**:32507-32512.
- Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SS, Caron MG, Lefkowitz RJ: **Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase.** *J Biol Chem* 1998, **273(2)**:685-688.
- Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, Lefkowitz RJ: **beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.** *J Biol Chem* 2006, **281(2)**:1261-1273.
- van der Blik AM, Redelmeier TE, Damke H, Tisdale EJ, Meyerowitz EM, Schmid SL: **Mutations in human dynamin block an intermediate stage in coated vesicle formation.** *J Cell Biol* 1993, **122(3)**:553-563.
- Ignatova EG, Belcheva MM, Bohn LM, Neuman MC, Coscia CJ: **Requirement of receptor internalization for opioid stimulation of mitogen-activated protein kinase: biochemical and immunofluorescence confocal microscopic evidence.** *J Neurosci* 1999, **19(1)**:56-63.
- Schramm NL, Limbird LE: **Stimulation of mitogen-activated protein kinase by G protein-coupled alpha(2)-adrenergic receptors does not require agonist-elicited endocytosis.** *J Biol Chem* 1999, **274(35)**:24935-24940.
- Iacovelli L, Salvatore L, Capobianco L, Picascia A, Barletta E, Storto M, Mariggio S, Sallèse M, Porcellini A, Nicoletti F, De Blasi A: **Role of G protein-coupled receptor kinase 4 and beta-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases.** *J Biol Chem* 2003, **278(14)**:12433-12442.
- Huhtaniemi I, Toppari J: **FSH regulation at the molecular and cellular levels: mechanisms of action and functional effects.** In *Sertoli cell biology* Elsevier Academic Press; 2005:155-171.
- Marion S, Robert F, Crépieux P, Martinat N, Troispoux C, Guillou F, Reiter E: **GRKs and beta-arrestins are relocalized and attenuate cAMP response to FSH in rat primary Sertoli cells.** *Biology of Reproduction* 2002, **66**:70-76.
- Nakamura K, Krupnick JG, Benovic JL, Ascoli M: **Signaling and phosphorylation-impaired mutants of the rat follitropin receptor reveal an activation- and phosphorylation-independent but arrestin-dependent pathway for internalization.** *J Biol Chem* 1998, **273(38)**:24346-24354.
- Nakamura K, Liu X, Ascoli M: **The rate of internalization of the gonadotropin receptors is greatly affected by the origin of the extracellular domain.** *J Biol Chem* 1999, **274(36)**:25426-25432.
- Lazari MF, Liu X, Nakamura K, Benovic JL, Ascoli M: **Role of G protein-coupled receptor kinases on the agonist-induced phosphorylation and internalization of the follitropin receptor.** *Molecular Endocrinology* 1999, **13**:866-878.
- Kishi H, Ascoli M: **Multiple distant amino acid residues present in the serpentine region of the follitropin receptor modulate the rate of agonist-induced internalization.** *J Biol Chem* 2000, **275(40)**:31030-31037.
- Troispoux C, Guillou F, Elalouf JM, Firsov D, Iacovelli L, De Blasi A, Combarnous Y, Reiter E: **Involvement of G-protein coupled receptor kinases and arrestins in desensitization to FSH action.** *Molecular Endocrinology* 1999, **9**:1599-1614.
- Simoni M, Gromoll J, Nieschlag E: **The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology.** *Endocr Rev* 1997, **18(6)**:739-773.
- Crépieux P, Marion S, Martinat N, Fafeur V, Vern YL, Kerboeuf D, Guillou F, Reiter E: **The ERK-dependent signalling is stage-specifically modulated by FSH, during primary Sertoli cell maturation.** *Oncogene* 2001, **20(34)**:4696-4709.

25. Das S, Maizels ET, DeManno D, St Clair E, Adam SA, Hunzicker-Dunn M: **A stimulatory role of cyclic adenosine 3',5'-monophosphate in follicle-stimulating hormone-activated mitogen-activated protein kinase signaling pathway in rat ovarian granulosa cells.** *Endocrinology* 1996, **137(3)**:967-974.
26. Cottom J, Salvador LM, Maizels ET, Reierstad S, Park Y, Carr DW, Davare MA, Hell JW, Palmer SS, Dent P, Kawakatsu H, Ogata M, Hunzicker-Dunn M: **Follicle-stimulating hormone activates extracellular signal-regulated kinase but not extracellular signal-regulated kinase kinase through a 100-kDa phosphotyrosine phosphatase.** *J Biol Chem* 2003, **278(9)**:7167-7179.
27. Closset J, Hennen G: **Porcine follitropin. Isolation and characterization of the native hormone and its alpha and beta subunits.** *Eur J Biochem* 1978, **86(1)**:105-113.
28. Bhalla VK, Reichert LE Jr: **FSH receptors in rat testis: chemical properties and solubilization studies.** *Curr Top Mol Endocrinol* 1974, **1**:201-220.
29. Kishi H, Krishnamurthy H, Galet C, Bhaskaran RS, Ascoli M: **Identification of a short linear sequence present in the C-terminal tail of the rat follitropin receptor that modulates arrestin-3 binding in a phosphorylation-independent fashion.** *J Biol Chem* 2002, **277(24)**:21939-21946.
30. Tohgo A, Pierce KL, Choy EW, Lefkowitz RJ, Luttrell LM: **beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation.** *J Biol Chem* 2002, **277(11)**:9429-9436.
31. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ: **Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference.** *Proc Natl Acad Sci USA* 2003, **100(4)**:1740-1744.
32. Ahn S, Wei H, Garrison TR, Lefkowitz RJ: **Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2.** *J Biol Chem* 2004, **279(9)**:7807-7811.
33. Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ: **Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor.** *Proc Natl Acad Sci USA* 2005, **102(5)**:1448-1453.
34. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Loomis CR, Spurney RF, Luttrell LM, Lefkowitz RJ: **Distinct beta-arrestin and G protein dependent pathways for parathyroid hormone receptor stimulated ERK1/2 activation.** *J Biol Chem* 2006, **281(16)**:10856-10864.
35. Goel R, Phillips-Mason PJ, Raben DM, Baldassare JJ: **alpha-Thrombin induces rapid and sustained Akt phosphorylation by beta-arrestin1-dependent and -independent mechanisms, and only the sustained Akt phosphorylation is essential for G1 phase progression.** *J Biol Chem* 2002, **277(21)**:18640-18648.
36. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG: **An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior.** *Cell* 2005, **122(2)**:261-273.
37. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW: **beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2.** *J Cell Biol* 2000, **148(6)**:1267-1281.
38. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ: **Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3.** *Science* 2000, **290(5496)**:1574-1577.
39. Sun Y, Cheng Z, Ma L, Pei G: **Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation.** *J Biol Chem* 2002, **277(51)**:49212-49219.
40. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ: **Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor.** *J Biol Chem* 2004, **279(34)**:35518-35525.
41. Wei H, Ahn S, Barnes WG, Lefkowitz RJ, Shenoy SK: **Stable interaction between beta-arrestin 2 and angiotensin type IA receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2.** *J Biol Chem* 2004, **279(46)**:48255-48261.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

